EMA firms up on how public hearings on marketed drugs will be run
This article was originally published in SRA
Executive Summary
The European Medicines Agency is inviting feedback on how its pharmacovigilance committee, the PRAC, should organize and conduct the public hearings that the committee is planning to hold as part of certain safety reviews of medicines1,2. The hearings would open the process of assessing medicines in the EU to the public for the first time3.